Pluvicto (Lutetium)

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent used for the treatment of adults with advanced cancer known as prostate-specific membrane antigen­–­positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) who have received therapy with androgen receptor pathway inhibition and taxane-based chemotherapy. 

Recommended Dosage: The recommended dosage is 7.4 GBq (200 mCi) administered intravenously (IV) every six weeks for up to six doses or until disease progression or unacceptable toxicity. Management of side effects may require temporary dose interruption (extending the dosing interval from every six weeks up to every ten weeks), dose reduction, or permanent discontinuation of therapy with Pluvicto injection. If a treatment delay because of a side effect persists for > 4 weeks, discontinue Pluvicto 1,000 MBq/mL treatment.

• Minimize radiation exposure during and after therapy with Lutetium Lu 177 vipivotide tetraxetan consistent with institutional good radiation safety practices and patient treatment procedures. Ensure patients elevate oral fluid consumption and instruct patients to void as often as possible to scale down bladder radiation. 
  
• Pluvicto can be responsible for causing severe and life-threatening myelosuppression, including thrombocytopenia, anemia, leukopenia, and neutropenia. Perform complete blood counts (CBC) before and throughout treatment. Withhold, reduce dose, or permanently discontinue therapy and clinically treat patients on behalf of the seriousness of myelosuppression.
  
• Pluvicto 1,000 MBq/mL (27 mCi/mL) can cause serious renal toxicity. Patients should remain well hydrated and urinate frequently prior to and after the administration of this medicine. Perform kidney function laboratory tests, including serum creatinine and calculated creatinine clearances, prior to and during this treatment.
  
• Based on its mechanism of action, Lutetium Lu 177 vipivotide tetraxetan can cause fetal harm. Male patients with female partners of reproductive age should use appropriate contraception methods throughout treatment and for 14 weeks after the final dose.
  
• Pluvicto treatment may cause infertility in males. The recommended cumulative dosage of 44.4 GBq results in a radiation-absorbed dose to the testes within the range where this medicine may be responsible for causing temporary or permanent infertility.

What documents are required to import PLUVICTO to India?

PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patient ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
  
• Import permit if applicable

PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is a (prescription medicine, prescription medication, or prescription drug) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Pluvicto in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can help facilitate the supply of PLUVICTO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Pluvicto 1,000 MBq/mL price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the PLUVICTO (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Pluvicto®?

Lutetium Lu 177 vipivotide tetraxetan is a Generic Name for the trade name drug Pluvicto®.

What is the Manufacturer’s Name of Pluvicto®?

Pluvicto® is manufactured by Novartis Pharmaceuticals Corporation.

Is Pluvicto® approved by the FDA?

Yes, Pluvicto® is approved by the FDA. Date of first approval: March 23, 2022.

Where can I get Pluvicto® at the best price in India?

To get the best Pluvicto price in India, kindly contact the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Pluvicto®, a medical prescription is needed from a treating physician.

What is the dosage and form of Pluvicto® supplied?

Pluvicto® is supplied as Injections: 1,000 MBq/mL (27 mCi/mL) in a single-dose vial for intravenous (IV) use. 

What are the most common side effects of Pluvicto®? 

The most common side effects of Pluvicto® are decreased appetite, fatigue, nausea, dry mouth, anemia, and constipation.

How much does Pluvicto® cost in India?

The cost of Pluvicto in India can vary. In order to procure this radioligand therapeutic agent legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Pluvicto®?

Store the vials below 30°C (86°F in the original package in order to protect them from ionizing radiation (lead shielding). Store it as per local and federal laws on radioactive materials. Do not freeze this drug.

Is it safe to buy Pluvicto® online in India?

Yes, one can buy Pluvicto online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Pluvicto® through legal channels.